Created at	Source	Raw Value	Validated value
April 29, 2021, 10:18 a.m.	usa	Frequency of treatment-emergent Serious Adverse Events (SAE) throughout the study and up to 12 months post-second dose immunization (Day 379).;Mean change from baseline in safety laboratory measures;Safety of a 2-dose regimen of VAX-001 when doses are given 14 days apart	Frequency of treatment-emergent Serious Adverse Events (SAE) throughout the study and up to 12 months post-second dose immunization (Day 379).;Mean change from baseline in safety laboratory measures;Safety of a 2-dose regimen of VAX-001 when doses are given 14 days apart
Oct. 26, 2020, 11:31 p.m.	usa	Safety of a 2-dose regimen of VAX-001 when doses are given 14 days apart;Mean change from baseline in safety laboratory measures;Frequency of treatment-emergent Serious Adverse Events (SAE) throughout the study and up to 6 months post-second dose immunization (Day 196).	Safety of a 2-dose regimen of VAX-001 when doses are given 14 days apart;Mean change from baseline in safety laboratory measures;Frequency of treatment-emergent Serious Adverse Events (SAE) throughout the study and up to 6 months post-second dose immunization (Day 196).